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s an Occluded Artery Better
han an Open One?*
avid Antoniucci, MD
lorence, Italy
he OAT (Occluded Artery Trial) study randomized 2,166
atients with subacute myocardial infarction and a persis-
ently occluded infarct-related artery (IRA) to percutaneous
oronary intervention (PCI) or to medical therapy (1). The
tudy did not show any benefit of PCI as compared with
edical therapy and did not confirm the so-called open
rtery hypothesis. The negative and unexpected results of
he OAT study raised several concerns. Among these, the
ow risk of the enrolled population that prevented the
emonstration of the hypothesized benefit of PCI. Major
xclusion criteria of the OAT study included left main or
-vessel disease, overt signs of heart failure, angina at rest,
nd severe inducible myocardial ischemia. Thus, the result-
ng profile of an OAT patient was defined by the lack of
ymptoms and a relatively low-risk of 1- or 2-vessel disease
ot associated with severe inducible myocardial ischemia.
he exclusion criteria at least in part explain the recruitment
roblems encountered by the investigators that resulted in a
ow enrollment rate and in the reduction of the original
lanned number of patients from 3,200 to 2,166.
See page 511
The study presented in this issue of JACC: Cardiovascular
nterventions by the OAT investigators assessed the impact
f randomization to PCI on outcome according to the
atient’s risk (2). The patient cohort was divided into risk
ertiles (low-, medium-, and high-risk) according to the
linical outcome, and then the impact of mechanical infarct
rtery recanalization was assessed in the 3 subgroups. The
rimary end point rate (composite of death, reinfarction,
ew York Heart Association functional class IV heart
ailure), and mortality rate were, respectively, 8.6% and
.5% for patients within the low-risk tertile, 13.4% and
.9% for patients within the medium-risk tertile, and 30.6%
nd 22.6% for patients within the high-risk tertile. The
tudy shows that there is no benefit of PCI as compared
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-v
ions or the American College of Cardiology.
From the Division of Cardiology, Careggi Hospital, Florence, Italy.ith medical therapy irrespective of the patient’s risk with
egard to the primary end point of the study as well as to the
stimated mortality at 5-year follow-up. Moreover, in the
ighest risk patient subgroup there was a trend toward more
dverse events in patients randomized to PCI as compared
ith medical therapy alone (33.9% vs. 27.3%, p  0.10).
This study not only confirms the unexpected and negative
esults of the main study (no benefit of PCI) but also
xtends the results to all patients regardless of their risk and
uggests that PCI may be responsible for a worse prognosis
or patients within the high-risk tertile who could theoret-
cally derive major benefit from revascularization as com-
ared with low- or medium-risk patients.
At first sight, the negative and in some way provocative
esults of this study could be scaled back by the fact that the
verall OAT patient cohort is not high risk, and the
tratification into 3 tertiles cannot overcome the criticism
hat the benefit of revascularization could not be demon-
trated even in the highest risk tertile because it does not
nclude “true” high-risk patients. This explanation however
s not tenable when considering that the risk stratification
ethod used by the investigators is rigorous and effective
nd allowed the identification of a subgroup of patients with
remarkable 5-year mortality of 22.6%.
However, are the results of the OAT study really unex-
ected? Two aspects of the main study as well as of the
urrent report were not sufficiently addressed.
First, the definition of a successful PCI was in several
ays arbitrary and may be easily challenged. The OAT
nvestigators include in the definition of successful PCI an
pen IRA with a Thrombolysis In Myocardial Infarction
TIMI) flow grade 1 or 2. All primary PCI studies,
ncluding the studies performed in the primary stenting
upported PCI era, have shown that a TIMI flow grade 3
s a strong predictor of mortality and major adverse events
3,4). A post-procedure TIMI flow grade 3 in patients
ithout cardiogenic shock should be considered as the
arker of an ineffective reperfusion due to an already
isrupted microvessel network before PCI, or more likely
ue to atherothrombotic embolization. The restoration of
IMI flow grade 3 by PCI, which is a prerequisite for an
ffective myocardial reperfusion but does not guarantee it,
as achieved in only 80% of patients. Thus, using current
tandard criteria for the definition of PCI success, primary
rocedure failure occurred in at least 20% of patients.
oreover, it is likely that in most of these patients, PCI was
ot only ineffective but also deleterious because of emboli-
ation into the microvessel network with subsequent no-
eflow, decreased retrograde flow from collateral circulation,
nd definite loss of viable myocardium. This hypothesis
eems to be confirmed by: 1) the high percentage of large
reas of viable myocardium (in the OAT viability substudy,
he large majority of the patients—69%—had evidence of
iable myocardium in the area supplied by the occluded
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522RA); and 2) the increased incidence of periprocedural
levation of cardiac enzymes (10% vs. 3.3%, p  0.001) and
f reinfarction (1.6% vs. 0.6%) in patients randomized to
CI as compared with patients randomized to medical
herapy (1).
The BRAVE (Beyond 12 Hours Reperfusion Alternative
valuation Trial)-2 study has demonstrated that residual
iability is very frequent in asymptomatic patients with
ubacute myocardial infarction, and more importantly, that
CI may be effective in salvaging viable myocardium (5). In
his study, 365 asymptomatic patients with acute myocardial
nfarction presenting between 12 and 48 h from the symp-
om onset were randomized to an invasive (PCI) or a
onservative treatment strategy. The primary end point of
he study was infarct size as assessed by sestamibi scintig-
aphy performed between 5 and 10 days after randomiza-
ion. The median time from symptom onset to hospital
dmission was 22 h. In the invasive group, 98.6% of patients
ad mechanical revascularization. The final infarct size was
maller in the invasive group as compared with the conser-
ative group (median 8% vs. 13%, p  0.001). The
cintigraphic substudy that included 261 patients who had
aired studies (before randomization and 5 to 10 days after
andomization) showed that the final smaller infarct size in
he invasive strategy group as compared with the conserva-
ive strategy group was due to increased myocardial salvage
n the former (salvage index: 0.44 and 0.23, respectively;
 0.001) because the baseline areas at risk were similar in
he 2 groups (6).
There is growing evidence that effective prevention of
mbolization during PCI in the setting of acute myocardial
nfarction results in a better myocardial reperfusion, in-
reased myocardial salvage, and improved survival. This
vidence is supported by several trials that used thrombec-
omy devices (7,8). The largest of these studies, the TAPAS
Thrombus Aspiration During Percutaneous Coronary In-
ervention in Acute Myocardial Infarction) trial, demon-
trated a significant increase in survival in patients random-
zed to manual thrombus aspiration as compared with
tandard PCI (9), and it is likely that the result of ongoing
rials will support the routine use of thrombectomy before
RA stenting.
In the setting of subacute myocardial infarction with a
ersistently thrombotic occlusion of IRA, the embolization
f an occlusive partially organized thrombus during PCI
ay have a worse impact on microvessel circulation than
resh acute thrombus embolization because the former is
ore refractory to spontaneous or pharmacological lysis.
he negative impact of PCI failure due to embolization on
linical outcome is well established from several PCI studies
nd, in the setting of acute myocardial infarction, is a strong
redictor of mortality. It is reasonable to conceive of a major
mpact of PCI failure due to embolization in high-risk
atients, as suggested by the OAT results.A second aspect that deserves a specific comment is that
n the subset of 379 patients with 2-vessel disease, a 2-vessel
CI was performed in only 75 patients, leaving most of
hem with an incomplete revascularization. Multivessel
isease and incomplete revascularization have a negative
mpact on clinical outcome after PCI (10–12), and these 2
ariables have the potential for some effect in the OAT
esults.
These 2 variables, PCI success defined according to
tandard criteria and completeness of revascularization in
atients with 2-vessel disease, were not considered in the
ultivariable models, leaving undefined their role in the
AT patient cohort.
Uncertainties regarding the potential benefit of routine
ate PCI for subacute myocardial infarction on left ventric-
lar remodeling and clinical outcome have long been a
atter of debate. It is easy to predict that the debate will not
nd after the results of the OAT study. The opposite results
rovided by a recent meta-analysis of 10 randomized studies
the OAT study was included) comparing PCI with medical
herapy in subacute myocardial infarction showed a strong
enefit of PCI in terms of improved survival (13).
Based on the evidence currently available, and thanks also
o the results of the OAT study, 2 statements can be made:
) no significant benefit can derive from mechanical IRA
eopening in the absence of viable myocardium; and 2)
iable myocardium can be salvaged if PCI restores an
dequate flow at the myocardial level. As a consequence,
CI, if performed, should not be driven by the interven-
ionalist’s oculo-occluded reflex, but supported by the as-
essment of a correct risk/benefit ratio. The most reasonable
pproach to an asymptomatic patient with subacute myo-
ardial infarction with a persistently occluded IRA is to
erform PCI only if myocardial viability or inducible isch-
mia is shown. The goal of the procedure should be effective
eperfusion at the myocardial level. From a technical point
f view, the procedure may be challenging, due to the high
isk of embolization and disruption of the microvessel
etwork that may jeopardize the collateral flow. The use of
echniques that decrease the risk of embolization should be
onsidered in all cases. Otherwise, the procedure could
ecome detrimental to the patient and prove that an
ccluded artery is better than an open one.
eprint requests and correspondence: Dr. David Antoniucci,
ivision of Cardiology, Careggi Hospital, Viale Morgagni,
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